Welcome to our dedicated page for Acadia Pharmaceuticals SEC filings (Ticker: ACAD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Acadia reports its financial results, material events, and governance changes as it develops and commercializes medicines for neurological and rare diseases.
Acadia’s current reports on Form 8‑K include items such as quarterly and year‑to‑date financial results and updates on board composition. For example, the company has filed 8‑Ks to furnish press releases announcing results for the three and nine months ended September 30, 2025, and for the three and six months ended June 30, 2025, under Item 2.02 (Results of Operations and Financial Condition. Another 8‑K discloses the resignation of a member of the Board of Directors under Item 5.02, noting that the resignation was not due to any dispute or disagreement with the company or the Board.
In addition to 8‑Ks, Acadia files annual and quarterly reports that typically contain detailed discussions of its commercial portfolio, including NUPLAZID for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE for Rett syndrome, as well as information on its pipeline programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, essential tremor, and other neuroscience and neuro‑rare indications. These filings generally address revenue composition, research and development spending, risk factors, and other information relevant to ACAD shareholders.
On Stock Titan, Acadia’s SEC filings are supplemented with AI-powered summaries that explain the key points of lengthy documents such as 10‑K annual reports, 10‑Q quarterly reports, and 8‑K current reports in plain language. Real-time updates from the SEC’s EDGAR system help users see new filings as they appear, while AI analysis highlights important changes in financial metrics, business priorities, and risk disclosures. Investors can also review insider-related filings such as Form 4 to monitor transactions by directors and officers in ACAD stock.
By combining original SEC documents with automated explanations, this filings page helps users quickly identify what Acadia is reporting about its financial condition, commercial performance, and development programs in neurological and rare diseases.
ACADIA Pharmaceuticals’ EVP and Chief Legal Officer Jennifer J. Rhodes reported equity transactions related to vested stock awards. On February 6, 2026, 12,944 restricted stock units were converted into common shares at an exercise price of $0, reflecting previously granted equity compensation.
On February 9, 2026, she sold 6,950 shares of common stock at a weighted average price of $23.38 per share in mandatory sales to cover withholding taxes and related items tied to the vesting. Following these transactions, she directly owned 7,609 shares of common stock and 12,945 restricted stock units, which continue to vest through February 2028.
Acadia Pharmaceuticals Inc. reported at the J.P. Morgan Healthcare Conference that it anticipates 2025 net sales will exceed $1 billion, in line with its prior guidance. The company shared this outlook in a corporate slide presentation and has made the slides available in the investors section of its website at ir.acadia.com. The update was furnished in a current report under results of operations and financial condition and accompanying Regulation FD disclosure.
ACADIA PHARMACEUTICALS INC (ACAD) executive vice president and chief financial officer reported equity transactions in company stock. On 11/17/2025, restricted stock units converted into 9,913 shares of common stock twice, increasing directly held shares. On 11/18/2025, the reporting person sold 10,262 shares of common stock at a weighted average price of $23.6907 per share, with sales made in multiple trades between $23.69 and $23.77. After these transactions, the reporting person directly beneficially owned 53,338 shares of common stock. The filing notes that certain sales were mandatory to cover withholding taxes related to restricted stock unit vesting and are intended to meet Rule 10b5-1(c) requirements. The restricted stock units generally vest over four years, with 37.5% vesting 18 months from grant, 12.5% on the second anniversary, and 25% on each of the third and fourth anniversaries, and some awards may vest earlier if the stock reaches a specified price over a set trading period.
ACADIA Pharmaceuticals (ACAD) principal accounting officer reported equity transactions involving company stock. On 11/17/2025, 3,966 restricted stock units converted into 3,966 shares of common stock at an exercise price of $0, twice, increasing directly held shares. On 11/18/2025, 4,084 shares of common stock were sold at a weighted average price of $23.6909 to cover withholding taxes and related items in connection with restricted stock unit vesting, under a Rule 10b5-1(c) plan. Following these transactions, the reporting person directly owned 25,058 shares of ACADIA common stock. Some restricted stock units feature a multi-year vesting schedule and may vest earlier if the stock reaches specified price targets over a set trading period.
ACADIA Pharmaceuticals (ACAD) director reported an open-market sale of 30,000 shares of common stock on 11/10/2025 at a weighted average price of $22.3661. The filing notes the trades occurred across multiple transactions within a range of $22.14 to $22.63. After the sale, the reporting person beneficially owns 4,041 shares, held directly.
ACADIA Pharmaceuticals reported higher profitability with growing product sales. Total revenue reached $278,633 (in thousands) for the quarter, up from $250,401 (in thousands) a year ago, driven by NUPLAZID at $177,530 and DAYBUE at $101,103 (each in thousands). Net income rose to $71,779 (in thousands), and diluted EPS was $0.42, reflecting stronger operations and a tax benefit.
Operating expenses were $242,877 (in thousands) as R&D increased to $87,829 and SG&A was $133,401 (each in thousands). Cost of product sales was $21,647 (in thousands), about 8% of net product sales. The effective tax rate was -61.0%, influenced by the One Big Beautiful Bill Act (OBBBA) and an accounting method change, boosting quarterly after‑tax results.
The balance sheet remained solid: cash and cash equivalents were $257,996 and investment securities were $589,023 (each in thousands). Stockholders’ equity improved to $917,272 (in thousands) from $732,793 at year‑end, supported by nine‑month operating cash flow of $158,567 (in thousands). Shares outstanding were 169,181,817 as of October 29, 2025.
Acadia Pharmaceuticals Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The information in this report and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated by reference except as specifically stated. The press release is dated November 5, 2025.
Acadia Pharmaceuticals Inc. announced that Daniel B. Soland has resigned from its Board of Directors and from his role as Chair of the Nominating and Corporate Governance Committee, effective October 30, 2025. The company stated that his resignation was not due to any dispute or disagreement regarding the company’s operations, policies, or practices.
Mark C. Schneyer, EVP & Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), reported two transactions in September 2025. On 09/12/2025 he acquired 6,815 shares of common stock upon vesting of performance stock units granted May 1, 2023, representing an incremental 25% of target and bringing total PSU vesting to 75% of target. Following that acquisition his beneficial ownership rose to 46,945 shares.
On 09/15/2025 he sold 3,498 shares at $23.65 per share to satisfy withholding taxes and related tax items associated with the PSU vesting, leaving him with 43,447 shares beneficially owned. The sale was reported as a mandatory sale intended to comply with Rule 10b5-1(c) provisions.
Acadia Pharmaceuticals director Elizabeth A. Garofalo reported a sale of 1,600 shares of Acadia common stock on 09/02/2025 at a weighted average price of $25.9753. Following the sale, the reporting person beneficially owned 25,382 shares. The filer notes the reported price is a weighted average for multiple transactions that ranged from $25.97 to $25.991 and offers to provide details on quantities sold at each price upon request. The Form 4 was signed by an attorney-in-fact on 09/03/2025.
FAQ
What is the current stock price of Acadia Pharmaceuticals (ACAD)?
What is the market cap of Acadia Pharmaceuticals (ACAD)?
